HK inno.N’s “K-CAB” Recognized as National Industry Pioneering Technology
November 7, 2023
HK inno.N’s “K-CAB” Recognized as National Industry Pioneering Technology
National Academy of Engineering of Korea recognizes 14 accounts across All Industries
K-CAB to be only technology to receive recognition from the Life Science Category
K-CAB, Korea’s 30th Novel Drug, redefines treatment landscape of Gastroesophageal Reflux Disease
Over 80 Clinical Studies, 50+ Journals in Korea and abroad, 450 Patents Korean Novel Drugs to Compete in the Global Market
K-CAB, a Korean novel drug developed by HK inno.N, was recognized for its prominent technology that has pioneered industrial advancements in Korea as a leader in the life science field.
HK inno.N’s K-CAB(CEO : Dal Won Kwak) was recognized by the National Academy of Engineering of Korea on the 7th as “2023’s Industry Leading Technology in the Life Science Category”
The National Academy of Engineering of Korea is an academic research institute established to promote the advancement of engineering and technology. The institute makes annual announcements by selecting outstanding technologies from various industries since 2006 for the purpose of sharing the latest technologies and industrial trends.
This year, a total of 14 cases were selected based on the evaluation of the future growth potential of technology, market contributions and social ripple effects from the fields of ▲electric/electronics, ▲energy/materials, ▲mobility, ▲construction/environment and ▲life science.
From the life science category, K-CAB, a novel drug for gastroesophageal reflux disease, was the only technology selected. K-CAB, Korea’s 30th Novel Drug, is the next generation, P-CAB digestive disease treatment drug that meets the unmet needs of current digestive disease treatments. K-CAB was selected as the outstanding technology after being highly recognized of for its economic and industrial impacts and promoting the public health by improving the quality of life for patients through the treatments of underlying diseases.
K-CAB made a grand entrance to the market with its strengths such as ▲Fast onset that enables efficacy within 30 minutes of administration, ▲potency and sustainability, ▲administrable regardless of food intake and ▲its safety profile and efficacy for 6-month-long administration. Since its launch in 2019, K-CAB has recorded accumulated prescriptions worth KRW \350.3 billion solely in Korea up to September this year which puts them as the No.1 gastroesophageal reflux disease drug for 5 consecutive years in the Korean market.
The company is also accelerating global expansion. Executing tech transfer agreements with the U.S. and China, the largest and second largest pharmaceutical markets in the world respectively, the company has expanded into Brazil and Mexico, the largest and second largest markets in the Central/South America. Accumulating 35 countries, which includes big global markets, K-CAB’s growing global presence is positioning K-CAB to be the first potential Korean global blockbuster drug in the pharmaceutical industry with Phase 3 clinical trials in the US advancing at a timely rate.
K-CAB is engaging in strategies through the development of multiple dosage forms and indication addition via clinical trials and development. And patent registrations in order to elevate its technical competitiveness.
Over 80 clinical studies either are in progress or have been completed, and 50-plus theses have been published by renowned journals in Korea and overseas. More than 450 patent applications are currently pending throughout the world. With extensive studies on indications, K-CAB carries the most indications among the P-CAB drugs in Korea. Moreover, the company addressed administration convenience by developing the ODT (orally disintegrated tablet) formulation, and is in the development of injections for emergency patients.
HK inno.n’s CEO Dal Won Kwak stated “K-CAB represents the integration of superb Korean R&D technologies for novel drugs and is expected of its potential for further growth as a global blockbuster novel drug. we are determined to contribute to further advancing the competitiveness of Korean novel drugs while improving the quality of life for patients through diversification of dosage forms and doses in addition to continuous research and development as a frontrunner leading the next-generation P-CAB-series drugs”.
The ’14 Selections from Industrial Technical Performance in 2023’ include ▲‘4K 120 Wireless OLED TV’ of LG Electronics, ▲the ‘world’s first UFS4.0 high-performance mobile storage products’ of Samsung Electronics, ▲‘UV cross-linked separator technology to enhance the safety of lithium secondary battery’ of LG Chemicals, ▲‘Multi-chamber air suspension system’ of Hyundai Mobis and ▲the ‘Korea’s first energy-saving wastewater treatment nitrogen-removal technology’ of BKT Korea.